Strides Pharma Q2 Revenue Rises 17% to Rs 14,297 Million
Strides Pharma Science reported record quarterly EBITDA of Rs 2,509 million. Ex-US markets surpassed US revenue for the first time.
Strides Pharma Science reported record quarterly EBITDA of Rs 2,509 million. Ex-US markets surpassed US revenue for the first time.